PRESS RELEASES

Humanigen Adds to Board of Directors

December 16, 2019

Humanigen’s GM-CSF Knockout Data Presented at the 2019 Annual Meeting of American Society of Hematology Receives Award

December 11, 2019

Humanigen Terminates Exploration of Potential Rights Offering

December 2, 2019

Humanigen to Present at the 2019 Stifel Healthcare Conference

November 15, 2019

Humanigen Announces Two Abstracts Accepted at the 2019 Annual Meeting of the Society for Neuro-Oncology, including Oral Presentation on its Next Generation EphA3-CAR-T

November 12, 2019

Humanigen Announces Two Lenzilumab Abstracts Accepted for Presentation at 2019 Annual Meeting of American Society of Hematology

November 6, 2019

Humanigen Announces Exploration of Potential Rights Offering

October 15, 2019

New ‘Blood Advances®’ Publication Supports Humanigen’s GM-CSF Neutralization Strategy with Lenzilumab in GvHD

October 8, 2019

Humanigen Secures Exclusive Worldwide License for the Prevention of GvHD through GM-CSF Neutralization from the University of Zurich

July 22, 2019

Humanigen Secures Exclusive Worldwide License to Gene-Editing Technology from Mayo Clinic to Improve CAR-T

July 2, 2019

©2020 Humanigen, Inc.  All rights reserved